Lymphoplasmacytic Lymphoma
- 1 January 2016
- book chapter
- book charpter
- Published by Elsevier BV
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014
- Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphomaExperimental and Molecular Pathology, 2014
- It is time to move forward with Waldenström!Blood, 2014
- Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results databaseBlood, 2014
- MYD88-independent growth and survival effects of Sp1 transactivation in Waldenström macroglobulinemiaBlood, 2014
- Dutcher bodies: cytoplasmic inclusions within the nucleusBritish Journal of Haematology, 2014
- The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesisBlood, 2014
- Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphomaBlood Cancer Journal, 2014
- Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenström's macroglobulinemiaBlood, 2014
- Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom MacroglobulinemiaAmerican Journal of Hematology, 2013